Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAGLE-i: [18F]PSMA-1007 PET/CT in High-Risk Prostate Cancer
NCT06122584Phase 3Recruiting
- Sponsor
- ABX advanced biochemical compounds
- Start
- Jun 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of radelumin in prostate cancer (PCa), sponsored by ABX advanced biochemical compounds. Started Jun 2024; status: recruiting.
02
Drugs
radelumin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06122584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06122584.